

In vitro susceptibilities of zygomycetes to conventional

Journal of Antimicrobial Chemotherapy

51, 45-52

DOI: [10.1093/jac/dkg020](https://doi.org/10.1093/jac/dkg020)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current concepts in antifungal susceptibility testing, Part II. <i>Clinical Microbiology Newsletter</i> , 2003, 25, 185-191.	0.4	0
3	Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3623-3626.	1.8	352
4	Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3647-3650.	1.4	156
5	Mucormycosis (Zygomycosis) in a Heart-Kidney Transplant Recipient: Recovery after Posaconazole Therapy. <i>Clinical Infectious Diseases</i> , 2003, 36, 1488-1491.	2.9	146
6	Use of Turbidimetric Growth Curves for Early Determination of Antifungal Drug Resistance of Filamentous Fungi. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4718-4725.	1.8	39
7	Utility of mould susceptibility testing. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 527-532.	1.3	30
8	Mucormicosis en PediatrÃa. <i>Revista Chilena De Infectologia</i> , 2004, 21, 17.	0.0	4
9	Wound infection due to <i>Absidia corymbifera</i> and <i>Candida albicans</i> with fatal outcome. <i>Medical Mycology</i> , 2004, 42, 373-378.	0.3	16
10	Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole. <i>Clinical Infectious Diseases</i> , 2004, 39, 743-746.	2.9	395
11	Disseminated Infection with <i>Prototheca zopfii</i> after Unrelated Stem Cell Transplantation for Leukemia. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4907-4908.	1.8	48
12	Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. <i>International Journal of Clinical Practice</i> , 2004, 58, 612-624.	0.8	130
13	Voriconazole for serious fungal infections. <i>International Journal of Clinical Practice</i> , 2004, 58, 74-80.	0.8	36
14	Lipid-based amphotericin in pulmonary zygomycosis: safety and efficacy of high exposure in a renal allograft recipient. <i>Transplant Infectious Disease</i> , 2004, 6, 183-187.	0.7	9
15	New options for the treatment of invasive fungal infections. <i>Seminars in Oncology</i> , 2004, 31, 91-98.	0.8	10
16	Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis. <i>Clinical Infectious Diseases</i> , 2004, 39, 584-587.	2.9	278
17	Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond <i>Candida albicans</i> and <i>Aspergillus fumigatus</i> . <i>Journal of Clinical Microbiology</i> , 2004, 42, 4419-4431.	1.8	623
18	Newer Systemic Antifungal Agents. <i>Drugs</i> , 2004, 64, 1997-2020.	4.9	274
19	Successful treatment of <i>Fusarium proliferatum</i> pneumonia with posaconazole in a lung transplant recipient. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 1451-1454.	0.3	66

#	ARTICLE	IF	CITATIONS
20	Bull's-eye cutaneous infarct of zygomycosis: A bedside diagnosis confirmed by touch preparation. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 996-1001.	0.6	47
21	Zygomycosis (mucormycosis): emerging clinical importance and new treatments. <i>Current Opinion in Infectious Diseases</i> , 2004, 17, 517-525.	1.3	221
22	Sinusitis, Periorbital Edema, and Ocular Proptosis. <i>Infectious Diseases in Clinical Practice</i> , 2005, 13, 255-260.	0.1	0
23	<i>Absidia</i> posttraumatic infection: successful treatment with posaconazole. <i>Journal of Infection</i> , 2005, 51, e135-e138.	1.7	31
25	In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. <i>Mycoses</i> , 2005, 48, 246-250.	1.8	57
27	Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. <i>European Journal of Pediatrics</i> , 2005, 164, 231-235.	1.3	28
28	Impact of community-associated, methicillin-resistant <i>Staphylococcus aureus</i> on management of the skin and soft tissue infections in children. <i>Current Infectious Disease Reports</i> , 2005, 7, 381-389.	1.3	16
29	Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 1016-1019.	1.3	25
30	Severe sensory neuropathy associated with long-term linezolid use. <i>Neurology</i> , 2005, 64, 926-927.	1.5	45
31	Caspofungin Inhibits <i>Rhizopus oryzae</i> 1,3- $\beta$ -D-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 721-727.	1.4	188
32	Activity of posaconazole in the treatment of central nervous system fungal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 745-755.	1.3	225
33	Voriconazole: review of a broad spectrum triazole antifungal agent. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1215-1229.	0.9	30
34	Diagnosis of Cutaneous Mucormycosis Due to <i>Rhizopus microsporus</i> by an Innovative PCR-Restriction Fragment-Length Polymorphism Method. <i>Clinical Infectious Diseases</i> , 2005, 41, 1362-1365.	2.9	31
35	Zygomycosis in a Tertiary Care Cancer Center in the Era of <i>Aspergillus</i> Active Antifungal Therapy: A Case-Control Observational Study of 27 Recent Cases. <i>Journal of Infectious Diseases</i> , 2005, 191, 1350-1360.	1.9	659
36	In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. <i>Medical Mycology</i> , 2005, 43, 179-185.	0.3	76
38	Posaconazole: a broad-spectrum triazole antifungal. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 775-785.	4.6	253
39	Liposomal amphotericin B: clinical experience and perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 167-181.	2.0	49
40	Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. <i>Clinical Microbiology Reviews</i> , 2005, 18, 556-569.	5.7	1,178

#	ARTICLE	IF	CITATIONS
41	Zygomycosis: An emerging fungal infection. American Journal of Health-System Pharmacy, 2005, 62, 2593-2596.	0.5	75
42	Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagnostic Microbiology and Infectious Disease, 2005, 52, 53-58.	0.8	43
43	Oral Bioavailability of Posaconazole in Fasted Healthy Subjects. Clinical Pharmacokinetics, 2005, 44, 211-220.	1.6	186
44	Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Review of Anti-Infective Therapy, 2005, 3, 467-487.	2.0	98
45	Fungal CNS infections in patients with hematologic malignancy. Expert Review of Anti-Infective Therapy, 2005, 3, 775-785.	2.0	42
46	Invasive Zygomycosis: Update on Pathogenesis, Clinical Manifestations, and Management. Infectious Disease Clinics of North America, 2006, 20, 581-607.	1.9	219
47	Lovastatin Has Significant Activity against Zygomycetes and Interacts Synergistically with Voriconazole. Antimicrobial Agents and Chemotherapy, 2006, 50, 96-103.	1.4	112
48	Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs, 2006, 15, 579-602.	1.9	77
49	Periorbital Zygomycosis (Mucormycosis) Treated With Posaconazole. American Journal of Ophthalmology, 2006, 142, 187-188.e3.	1.7	41
52	Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatric Critical Care Medicine, 2006, 7, 482-485.	0.2	31
53	Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatric Blood and Cancer, 2006, 47, 959-963.	0.8	16
54	Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses, 2006, 49, 27-30.	1.8	52
55	Mucormycosis: an emerging disease?. Clinical Microbiology and Infection, 2006, 12, 7-23.	2.8	109
56	Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 8-13.	1.3	122
57	Zygomycosis: the re-emerging fungal infection. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 215-229.	1.3	325
58	Rhizomucor: a model for the emerging importance of mould susceptibility testing. Clinical Microbiology Newsletter, 2006, 28, 150-152.	0.4	0
59	New antifungal therapies. Clinical Microbiology Newsletter, 2006, 28, 169-173.	0.4	2
60	Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. Liver Transplantation, 2006, 12, 1711-1714.	1.3	20

#	ARTICLE	IF	CITATIONS
61	Successful treatment of invasive Rhizopus infection in a child with thalassemia. <i>Medical Mycology</i> , 2006, 44, 771-775.	0.3	5
62	Diagnostic challenge of zygomycosis in compromised hosts. <i>Medical Mycology</i> , 2006, 44, 19-24.	0.3	9
63	No Effect of Pyridoxine on the Incidence of Myelosuppression during Prolonged Linezolid Treatment. <i>Clinical Infectious Diseases</i> , 2006, 43, e89-e91.	2.9	26
64	Peritonitis due to <i>Cunninghamella bertholletiae</i> in a patient undergoing continuous ambulatory peritoneal dialysis. <i>Journal of Medical Microbiology</i> , 2006, 55, 115-118.	0.7	21
65	Genetic Identification of the Main Opportunistic Mucorales by PCR-Restriction Fragment Length Polymorphism. <i>Journal of Clinical Microbiology</i> , 2006, 44, 805-810.	1.8	83
66	In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2009-2015.	1.4	416
67	Posaconazole as Salvage Therapy for Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 126-133.	1.4	523
68	Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1881-1883.	1.4	102
69	Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. <i>Journal of Clinical Microbiology</i> , 2006, 44, 553-560.	1.8	49
70	Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 917-921.	1.4	279
71	Molecular Identification of Zygomycetes from Culture and Experimentally Infected Tissues. <i>Journal of Clinical Microbiology</i> , 2006, 44, 340-349.	1.8	158
72	Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 658-666.	1.4	264
73	Comparison of Three Commercial Assays and a Modified Disk Diffusion Assay with Two Broth Microdilution Reference Assays for Testing Zygomycetes, <i>Aspergillus</i> spp., <i>Candida</i> spp., and <i>Cryptococcus neoformans</i> with Posaconazole and Amphotericin B. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3616-3622.	1.8	77
74	In Vitro Activities of Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole against 45 Clinical Isolates of Zygomycetes: Comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1126-1129.	1.4	63
75	Posaconazole: A Broad-Spectrum Triazole Antifungal Agent. <i>Clinical Infectious Diseases</i> , 2007, 45, 1610-1617.	2.9	201
76	In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2587-2590.	1.4	265
77	Does Linezolid Inhibit Its Own Metabolism?—Population Pharmacokinetics As a Tool to Explain the Observed Nonlinearity in Both Healthy Volunteers and Septic Patients. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1816-1823.	1.7	79
78	Carbon Assimilation Profiles as a Tool for Identification of Zygomycetes. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1433-1439.	1.8	52

#	ARTICLE	IF	CITATIONS
79	Rapid Bactericidal Activity of Daptomycin against Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Peritonitis in Mice as Measured with Bioluminescent Bacteria. Antimicrobial Agents and Chemotherapy, 2007, 51, 1787-1794.	1.4	71
80	A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1019-22.	1.4	20
82	Linezolid: effectiveness and safety for approved and off-label indications. Expert Opinion on Pharmacotherapy, 2007, 8, 2381-2400.	0.9	32
83	Posaconazole: a new broad-spectrum antifungal agent. Expert Opinion on Pharmacotherapy, 2007, 8, 1167-1178.	0.9	39
84	Multicenter Evaluation of a New Disk Agar Diffusion Method for Susceptibility Testing of Filamentous Fungi with Voriconazole, Posaconazole, Itraconazole, Amphotericin B, and Caspofungin. Journal of Clinical Microbiology, 2007, 45, 1811-1820.	1.8	120
85	Current status of antifungal susceptibility testing methods. Medical Mycology, 2007, 45, 569-587.	0.3	107
86	Recent advances and challenges in the treatment of invasive fungal infections. International Journal of Antimicrobial Agents, 2007, 30, 487-495.	1.1	104
87	Fatal pulmonary infection due to Rhizopus microsporus in a patient with sickle disease. Journal De Mycologie Medicale, 2007, 17, 63-64.	0.7	2
88	Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae. Journal of Infection, 2007, 55, e33-e36.	1.7	32
89	In Vitro antifungal activity of extract and plumbagin from the stem bark of Diospyros crassiflora Hiern (Ebenaceae). Phytotherapy Research, 2007, 21, 671-674.	2.8	75
90	Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2007, 48, 349-353.	0.8	19
91	Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transplant Infectious Disease, 2007, 9, 89-96.	0.7	36
92	Posaconazole as Salvage Therapy in a Patient with Disseminated Zygomycosis: Case Report and Review of the Literature. Pharmacotherapy, 2007, 27, 290-298.	1.2	41
93	Treatment options in emerging mold infections. Current Infectious Disease Reports, 2008, 10, 473-479.	1.3	7
94	Treatment options in emerging mold infections. Current Fungal Infection Reports, 2008, 2, 74-80.	0.9	3
95	Current challenges in the management of invasive fungal infections. Journal of Infection and Chemotherapy, 2008, 14, 77-85.	0.8	145
96	Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplantation, 2008, 42, 551-552.	1.3	43
97	Liposomal amphotericin B: what is its role in 2008?. Clinical Microbiology and Infection, 2008, 14, 71-83.	2.8	60

#	ARTICLE	IF	CITATIONS
98	Recommendations for the treatment of established fungal infections. Internal Medicine Journal, 2008, 38, 496-520.	0.5	58
99	Linezolid for the treatment of drug-resistant infections. Expert Review of Anti-Infective Therapy, 2008, 6, 825-848.	2.0	27
100	Present situation in the treatment of invasive fungal infection. International Journal of Antimicrobial Agents, 2008, 32, S167-S171.	1.1	22
101	Current challenges in treating MRSA: what are the options?. Expert Review of Anti-Infective Therapy, 2008, 6, 601-618.	2.0	13
102	Treatment and recurrence management of staphylococcal infections: community-acquired MRSA. Expert Review of Anti-Infective Therapy, 2008, 6, 909-915.	2.0	5
103	Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent. Expert Review of Clinical Pharmacology, 2008, 1, 479-489.	1.3	6
104	Resistance to Antifungal Agents: Mechanisms and Clinical Impact. Clinical Infectious Diseases, 2008, 46, 120-128.	2.9	473
105	Activity of BAL 4815 against filamentous fungi. Journal of Antimicrobial Chemotherapy, 2008, 61, 1083-1086.	1.3	23
106	Medication-Related Complications in the Trauma Patient. Journal of Intensive Care Medicine, 2008, 23, 91-108.	1.3	11
107	Failure of Deferasirox, an Iron Chelator Agent, Combined with Antifungals in a Case of Severe Zygomycosis. Antimicrobial Agents and Chemotherapy, 2008, 52, 1585-1586.	1.4	30
108	Linezolid for the treatment of skin and soft-tissue infections. Expert Review of Dermatology, 2008, 3, 539-548.	0.3	1
109	Posaconazole Enhances the Activity of Amphotericin B against Hyphae of Zygomycetes In Vitro. Antimicrobial Agents and Chemotherapy, 2008, 52, 2636-2638.	1.4	62
110	Comparison of Neo-Sensitabs Tablet Diffusion Assay with CLSI Broth Microdilution M38-A and Disk Diffusion Methods for Testing Susceptibility of Filamentous Fungi with Amphotericin B, Caspofungin, Itraconazole, Posaconazole, and Voriconazole. Journal of Clinical Microbiology, 2008, 46, 1793-1803.	1.8	33
111	Comparative <i>in vitro</i> activities of posaconazole, voriconazole, itraconazole, and amphotericin B against <i>Aspergillus</i> and <i>Rhizopus</i> , and synergy testing for <i>Rhizopus</i> . Medical Mycology, 2008, 46, 567-573.	0.3	62
112	Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. Journal of Antimicrobial Chemotherapy, 2008, 61, 616-620.	1.3	87
113	A Patient With an Unusual Surgical Site Infection. Infectious Diseases in Clinical Practice, 2008, 16, 174-177.	0.1	0
114	Primary Cutaneous Zygomycosis in a Burns Patient: A Review. Journal of Burn Care and Research, 2008, 29, 286-290.	0.2	39
115	<i>Absidia corymbifera</i> Fungal Infection in Burns: A Case Report and Review of the Literature. Journal of Burn Care and Research, 2008, 29, 416-419.	0.2	25

#	ARTICLE	IF	CITATIONS
116	Antifungal Therapy Strategies in Hematopoietic Stem-Cell Transplant Recipients: Early Treatment Options for Improving Outcomes. <i>Transplantation</i> , 2008, 86, 183-191.	0.5	4
117	Posaconazole in the management of refractory invasive fungal infections. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 747-757.	0.9	25
118	Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i> 322-329.	0.7	79
119	Sequence-Based Identification of <i>Aspergillus</i> , <i>Fusarium</i> , and <i>Mucorales</i> Species in the Clinical Mycology Laboratory: Where Are We and Where Should We Go from Here?. <i>Journal of Clinical Microbiology</i> , 2009, 47, 877-884.	1.8	299
120	Molecular Identification and <i>In Vitro</i> Antifungal Susceptibilities of 28 Zygomycetes Isolates: FIMUA-ECMM Survey of Zygomycosis in Italy. <i>Journal of Chemotherapy</i> , 2009, 21, 363-364.	0.7	2
121	Increased Virulence of Zygomycetes Organisms Following Exposure to Voriconazole: A Study Involving Fly and Murine Models of Zygomycosis. <i>Journal of Infectious Diseases</i> , 2009, 199, 1399-1406.	1.9	117
122	<i>Mucor circinelloides</i> as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1244-1248.	1.8	37
123	Molecular and Phenotypic Evaluation of <i>Lichtheimia corymbifera</i> (Formerly <i>Absidia</i> ) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50</i> ramosa. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3862-3870.	1.8	86
124	Activity of Posaconazole and Other Antifungal Agents against <i>Mucorales</i> Strains Identified by Sequencing of Internal Transcribed Spacers. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1686-1689.	1.4	77
125	ZYGOMYCOSIS: Current approaches to management of patients with haematological malignancies. <i>British Journal of Haematology</i> , 2009, 146, 597-606.	1.2	29
126	Zygomycosis and diabetes mellitus. <i>Clinical Microbiology and Infection</i> , 2009, 15, 21-25.	2.8	36
127	<i>In vitro</i> activity of antifungals against Zygomycetes. <i>Clinical Microbiology and Infection</i> , 2009, 15, 71-76.	2.8	79
128	Recent Advances in the Management of Mucormycosis: From Bench to Bedside. <i>Clinical Infectious Diseases</i> , 2009, 48, 1743-1751.	2.9	435
129	A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes <i>in vitro</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 361-364.	0.8	13
130	Fatal <i>Rhizopus</i> Pneumonia in Allogeneic Stem Cell Transplant Patients Despite Posaconazole Prophylaxis: Two Cases and Review of the Literature. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 991-995.	2.0	47
131	Update on the safety of linezolid. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 485-491.	1.0	25
132	Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 165-181.	2.0	14
133	An increasing trend of cutaneous zygomycosis caused by <i>Mycoclados corymbifer</i> (formerly <i>Absidia corymbifera</i> ): report of two cases and review of primary cutaneous <i>Mycoclados</i> infections. <i>Medical Mycology</i> , 2009, 47, 532-538.	0.3	24



#	ARTICLE	IF	CITATIONS
134	Terbinafine: a pharmacological and clinical review. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2723-2733.	0.9	62
135	Appearance of ring sideroblasts in bone marrow during linezolid therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 480-482.	1.5	8
136	Invasive mold infections: recent advances in management approaches. <i>Leukemia and Lymphoma</i> , 2009, 50, 703-715.	0.6	28
137	Post-traumatic infection of the lower limb caused by rare Enterobacteriaceae and Mucorales in a young healthy male. <i>International Journal of Infectious Diseases</i> , 2009, 13, e57-e60.	1.5	24
138	Nasofacial Entomophthoromycosis. <i>Infectious Diseases in Clinical Practice</i> , 2009, 17, 44-47.	0.1	0
139	Report of a Successful Treatment of Pulmonary <i>Cunninghamella bertholletiae</i> Infection With Liposomal Amphotericin and Posaconazole in a Child With GvHD and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 85-87.	0.3	21
140	Successful Treatment of Cutaneous Zygomycosis With Intravenous Amphotericin B Followed by Oral Posaconazole in a Multivisceral Transplant Recipient. <i>Transplantation</i> , 2010, 90, 1133-1135.	0.5	25
141	Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model. <i>Journal of Infection and Chemotherapy</i> , 2010, 16, 388-395.	0.8	7
142	Recent Advances in the Treatment of Mucormycosis. <i>Current Infectious Disease Reports</i> , 2010, 12, 423-429.	1.3	136
143	Molecular phylogenetic diversity of the emerging mucoralean fungus <i>Apophysomyces</i> : Proposal of three new species. <i>Revista Iberoamericana De Micologia</i> , 2010, 27, 80-89.	0.4	87
144	Diagnostic challenges and recent advances in the early management of invasive fungal infections. <i>European Journal of Haematology</i> , 2010, 84, 281-290.	1.1	43
145	Disseminated <i>Rhizopus microsporus</i> infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection. <i>Transplant Infectious Disease</i> , 2010, 12, 269-272.	0.7	17
146	Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. <i>Drug Design, Development and Therapy</i> , 2010, 4, 299.	2.0	5
147	<i>Apophysomyces elegans</i> : Epidemiology, Amplified Fragment Length Polymorphism Typing, and <i>In Vitro</i> Antifungal Susceptibility Pattern. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4580-4585.	1.8	67
148	Antifungal Susceptibility Profile of Human-Pathogenic Species of <i>Lichtheimia</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3058-3060.	1.4	26
149	Molecular Detection and Identification of <i>Zygomycetes</i> Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation. <i>Journal of Clinical Microbiology</i> , 2010, 48, 2043-2046.	1.8	83
150	Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. <i>Medical Mycology</i> , 2010, 48, 245-254.	0.3	32
151	In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2158-2163.	1.3	27

#	ARTICLE	IF	CITATIONS
152	Acute Cardiac Failure due to Intra-Atrial Mass Caused by Zygomycetes in an Immunocompromised Paediatric Patient. <i>Case Reports in Medicine</i> , 2010, 2010, 1-5.	0.3	5
153	Clinical Experience with Linezolid at a Large Academic Medical Center: A Case Series and Review of the Literature. <i>Hospital Pharmacy</i> , 2010, 45, 916-926.	0.4	3
154	HIV-related cryptococcal meningitis in resource-limited settings. <i>HIV Therapy</i> , 2010, 4, 567-576.	0.6	2
155	Managing fungal and viral infections in pediatric leukemia. <i>Expert Review of Hematology</i> , 2010, 3, 603-624.	1.0	1
156	Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment. <i>Drug Metabolism and Drug Interactions</i> , 2010, 25, 41-7.	0.3	18
157	<i>In Vitro</i> Antifungal Activities of Bis(Alkylpyridinium)Alkane Compounds against Pathogenic Yeasts and Molds. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3233-3240.	1.4	10
158	Antibacterial oxazolidinones: emerging structure-toxicity relationships. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 565-574.	2.0	30
159	Fatal peritonitis caused by <i>Rhizopus microsporus</i> . <i>Medical Mycology</i> , 2010, 48, 1096-1098.	0.3	9
160	Identification and susceptibility of <i>Rhizomucor</i> spp. isolated from patients with cutaneous zygomycosis in China. <i>Medical Mycology</i> , 2011, 49, 1-7.	0.3	11
161	Posaconazole for the treatment of mucormycosis. <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 465-473.	1.1	18
162	Mucormycosis. , 2011, , 597-602.		1
163	Epidemiology and treatment approaches in management of invasive fungal infections. <i>Clinical Epidemiology</i> , 2011, 3, 175.	1.5	142
164	Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1859-1867.	2.8	566
165	Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. <i>European Journal of Haematology</i> , 2011, 87, 289-301.	1.1	32
166	A Case of Rhinoorbital Mucormycosis in a Leukemic Patient with a Literature Review from Turkey. <i>Mycopathologia</i> , 2011, 172, 397-405.	1.3	13
167	Management of invasive fungal infections: a role for polyenes. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 457-465.	1.3	76
168	Mucormycosis Caused by Unusual Mucormycetes, Non- <i>Rhizopus</i> , - <i>Mucor</i> , and - <i>Lichtheimia</i> Species. <i>Clinical Microbiology Reviews</i> , 2011, 24, 411-445.	5.7	340
169	How Does Antifungal Pharmacology Differ for Mucormycosis Versus Aspergillosis?. <i>Clinical Infectious Diseases</i> , 2012, 54, S67-S72.	2.9	51

#	ARTICLE	IF	CITATIONS
170	Unusual Facial Mutilation Due to Rhinoentomophthoromycosis. <i>Infectious Diseases in Clinical Practice</i> , 2012, 20, 341-344.	0.1	0
171	Future Directions in Mucormycosis Research. <i>Clinical Infectious Diseases</i> , 2012, 54, S79-S85.	2.9	42
172	Invasive <i>Apophysomyces variabilis</i> Infection in a Burn Patient. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2814-2817.	1.8	20
173	Antifungal Susceptibility and Phylogeny of Opportunistic Members of the Order Mucorales. <i>Journal of Clinical Microbiology</i> , 2012, 50, 66-75.	1.8	134
174	Direct Analysis and Identification of Pathogenic <i>Lichtheimia</i> Species by Matrix-Assisted Laser Desorption Ionization–Time of Flight Analyzer-Mediated Mass Spectrometry. <i>Journal of Clinical Microbiology</i> , 2012, 50, 419-427.	1.8	75
175	<i>In vitro</i> interactions of amantadine hydrochloride, R(-)-deprenyl hydrochloride and valproic acid sodium salt with antifungal agents against filamentous fungal species causing central nervous system infection. <i>Acta Biologica Hungarica</i> , 2012, 63, 490-500.	0.7	4
176	Invasive Mycoses: Strategies for Effective Management. <i>American Journal of Medicine</i> , 2012, 125, S25-S38.	0.6	68
177	Isothermal microcalorimetry for antifungal susceptibility testing of Mucorales, <i>Fusarium</i> spp., and <i>Scedosporium</i> spp.. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 330-337.	0.8	19
178	Diabetes and mucormycosis: A complex interplay. <i>Diabetes and Metabolism</i> , 2012, 38, 193-204.	1.4	110
179	Antifungal Activity of <i>Thymus vulgaris</i> L. Essential Oil and Its Constituent Phytochemicals against <i>Rhizopus oryzae</i> : Interaction with Ergosterol. <i>Molecules</i> , 2012, 17, 14418-14433.	1.7	118
180	The Mycoses. , 2012, , 531-544.		0
181	Oxazolidinone Antibacterial Agents. , 2012, , 271-299.		6
182	Rhino-Orbital-Cerebral Mucormycosis. <i>Current Infectious Disease Reports</i> , 2012, 14, 423-434.	1.3	128
183	Equine keratomycosis in Japan. <i>Veterinary Ophthalmology</i> , 2013, 16, 1-9.	0.6	32
184	Rare Invasive Fungal Infections: Epidemiology, Diagnosis and Management. <i>Current Fungal Infection Reports</i> , 2013, 7, 351-360.	0.9	26
185	A non-fatal case of invasive zygomycete ( <i>Lichtheimia corymbifera</i> ) infection in an allogeneic haematopoietic cell transplant recipient. <i>Apmis</i> , 2013, 121, 456-459.	0.9	3
186	Development of a single tube multiplex real-time PCR to detect the most clinically relevant Mucormycetes species. <i>Clinical Microbiology and Infection</i> , 2013, 19, E1-E7.	2.8	79
187	Emergence of <i>Cunninghamella</i> As a Pathogenic Invasive Mold Infection in Allogeneic Transplant Recipients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 622-628.	0.2	9

#	ARTICLE	IF	CITATIONS
188	Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). <i>Haematologica</i> , 2013, 98, 492-504.	1.7	282
189	Efficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3340-3347.	1.4	54
190	Focus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases. <i>Mycoses</i> , 2013, 56, 236-240.	1.8	16
191	Current Status of Diagnosis of Mucormycosis: Update on Molecular Methods. <i>Current Fungal Infection Reports</i> , 2014, 8, 353-359.	0.9	4
192	Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. <i>Internal Medicine Journal</i> , 2014, 44, 1333-1349.	0.5	87
193	Zigomicose rino facial: relato de caso. <i>Einstein (Sao Paulo, Brazil)</i> , 2014, 12, 347-350.	0.3	3
194	Why is mucormycosis more difficult to cure than more common mycoses?. <i>Clinical Microbiology and Infection</i> , 2014, 20, 74-81.	2.8	115
195	Comparative Pharmacodynamics of Posaconazole in Neutropenic Murine Models of Invasive Pulmonary Aspergillosis and Mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6767-6772.	1.4	42
196	Disseminated Staphylococcal Disease in Healthy Children—Experience from Two Tertiary Care Hospitals of West Bengal. <i>Indian Journal of Pediatrics</i> , 2014, 81, 133-137.	0.3	9
197	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014, 20, 5-26.	2.8	547
198	Entomophthoromycosis: a challenging emerging disease. <i>Mycoses</i> , 2014, 57, 132-137.	1.8	41
199	Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs. <i>Mycoses</i> , 2014, 57, 40-47.	1.8	26
200	Methicillin-resistant <i>Staphylococcus aureus</i> -related Septic Pulmonary Embolism and Sacroiliitis Treated with Long-term Linezolid in a Patient with Adult-onset Still's Disease. <i>Internal Medicine</i> , 2014, 53, 1023-1027.	0.3	6
201	Synthesis and <i>In Vitro</i> Evaluation of the Antitubercular and Antibacterial Activity of Novel Oxazolidinones Bearing Octahydrocyclopenta[ <i>c</i> ]pyrrol-2-yl Moieties. <i>Chemical and Pharmaceutical Bulletin</i> , 2014, 62, 1214-1224.	0.6	7
202	Agents of Mucormycosis and Entomophthoromycosis. , 2015, , 2909-2919.e3.		11
203	Mucormycosis (Zygomycosis). , 2015, , 159-168.		0
204	Human Fungal Pathogens of Mucorales and Entomophthorales. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a019562-a019562.	2.9	69
205	Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications. <i>Drug Safety</i> , 2015, 38, 253-269.	1.4	71

#	ARTICLE	IF	CITATIONS
206	Combination Therapy for the Treatment of Mucormycosis: Examining the Evidence. <i>Current Fungal Infection Reports</i> , 2015, 9, 94-110.	0.9	4
207	Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2015, 34, 1289-1301.	1.3	32
208	Etest Cannot Be Recommended for <i>In Vitro</i> Susceptibility Testing of Mucorales. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3663-3665.	1.4	29
209	Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 611-615.	0.8	15
210	The Role of Telavancin in Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. <i>Clinical Infectious Diseases</i> , 2015, 61, S79-S86.	2.9	18
211	ANTIMICROBIAL ACTIVITY OF STREPTOMYCES SP. PJ90 ISOLATED FROM SOIL IN NORTHEAST THAILAND. <i>Jurnal Teknologi (Sciences and Engineering)</i> , 2016, 78, .	0.3	0
212	HEMATOPOETIC STEM CELL RESPONSE TO STIMULATION OF EXTRACTS FROM ANIMAL MATERIALS. <i>Jurnal Teknologi (Sciences and Engineering)</i> , 2016, 78, .	0.3	0
213	Oxidation of linezolid by permanganate in acidic medium: Pd(II) catalysis, kinetics and pathways. <i>Progress in Reaction Kinetics and Mechanism</i> , 2016, 41, 245-257.	1.1	2
214	Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3540-3547.	1.3	19
215	Emerging diagnostic and therapeutic options for treating mucormycosis. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1253-1261.	0.5	4
216	A Patient with Newly Diagnosed Diabetes Presenting with Sino-Orbital Mucormycosis. <i>AACE Clinical Case Reports</i> , 2016, 2, e41-e45.	0.4	3
217	<i>Cunninghamella bertholletiae</i> Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2016, 181, 753-758.	1.3	6
218	In vitro antifungal susceptibility of clinical species belonging to <i>Aspergillus</i> genus and <i>Rhizopus oryzae</i> . <i>Journal De Mycologie Medicale</i> , 2016, 26, 17-21.	0.7	6
219	Antifungal Agents. <i>Infectious Disease Clinics of North America</i> , 2016, 30, 51-83.	1.9	264
220	Opportunistic Mycoses. , 2016, , 661-681.e16.		2
221	Antifungal resistance in mucorales. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 617-621.	1.1	87
222	Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14 $\alpha$ -demethylase. <i>Scientific Reports</i> , 2017, 7, 15898.	1.6	59
223	Spectrophotometric reading of EUCAST antifungal susceptibility testing of <i>Aspergillus fumigatus</i> . <i>Clinical Microbiology and Infection</i> , 2017, 23, 98-103.	2.8	18

#	ARTICLE	IF	CITATIONS
224	Occurrence and species distribution of pathogenic Mucorales in unselected soil samples from France. <i>Medical Mycology</i> , 2018, 56, 315-321.	0.3	17
225	Synthesis, Self-Assembly, and Biomedical Applications of Antimicrobial Peptide-Polymer Conjugates. <i>Biomacromolecules</i> , 2018, 19, 1701-1720.	2.6	195
226	Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones. <i>Clinical Pharmacokinetics</i> , 2018, 57, 559-575.	1.6	87
227	<i>In Vitro</i> Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant <i>Aspergillus</i> spp. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	12
228	Linezolid-induced pure red cell aplasia: a case report and literature review. <i>Journal of International Medical Research</i> , 2018, 46, 4837-4844.	0.4	11
229	Therapy of Mucormycosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2018, 4, 90.	1.5	133
230	Invasive Fungal Sinusitis in Immunocompromised Hosts. , 2018, , 177-188.		0
231	Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for <i>Mucorales</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	6
232	Identification of Mucorales by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. <i>Journal of Fungi (Basel, Switzerland)</i> , 2019, 5, 56.	1.5	17
233	Mucormycosis. , 2019, , 121-154.		2
234	Mucormycosis. , 2019, , 577-589.		5
235	A Revised Species Concept for Opportunistic <i>Mucor</i> Species Reveals Species-Specific Antifungal Susceptibility Profiles. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	34
236	Antifungal combinations in Mucorales: A microbiological perspective. <i>Mycoses</i> , 2019, 62, 746-760.	1.8	30
237	Posaconazole salvage therapy: The Posifi study. <i>Mycoses</i> , 2019, 62, 526-533.	1.8	9
238	Antifungal-resistant Mucorales in different indoor environments. <i>Mycology</i> , 2019, 10, 75-83.	2.0	22
239	Contemporary management and clinical outcomes of mucormycosis: A systematic review and meta-analysis of case reports. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 589-597.	1.1	79
240	Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases. <i>Supportive Care in Cancer</i> , 2020, 28, 2157-2161.	1.0	7
241	Occupational Exposures to Organic Dust in Irish Bakeries and a Pizzeria Restaurant. <i>Microorganisms</i> , 2020, 8, 118.	1.6	20

#	ARTICLE	IF	CITATIONS
242	&lt;i>&lt;i>In Vitro&lt;/i>&lt;/i> Susceptibility of Dermatophytes to Anti-Fungal Drugs and Aqueous &lt;i>&lt;i>Acacia nilotica&lt;/i>&lt;/i> Leaf Extract in Lagos, Nigeria. Journal of Biomedical Science and Engineering, 2021, 14, 74-82.	0.2	4
244	Mucormycosis. Infectious Disease Clinics of North America, 2021, 35, 435-452.	1.9	54
245	A mouse air pouch model for evaluating the anti-bacterial efficacy of phage MR-5 in resolving skin and soft tissue infection induced by methicillin-resistant Staphylococcus aureus. Folia Microbiologica, 2021, 66, 959-972.	1.1	5
246	Entomophthoromycosis Presenting as a Nasal Mass. Indian Journal of Otolaryngology and Head and Neck Surgery, 0, , 1.	0.3	0
247	Azoles. , 2011, , 61-93.		1
248	Amphotericin B: Polyene Resistance Mechanisms. , 2009, , 295-305.		11
249	Zygomycosis (Mucormycosis). , 2008, , 227-243.		2
251	Treatment of Endocarditis. , 2016, , 181-280.		1
252	Amphotericin B: Polyene Resistance Mechanisms. , 2017, , 387-395.		4
253	Molecular Barcoding of Microscopic Fungi with Emphasis on the Mucoralean Genera Mucor and Rhizopus. , 2010, , 213-250.		7
254	Oxazolidin-2-Ones: Antibacterial Activity and Chemistry. , 2014, , 247-266.		1
255	Agents of Mucormycosis and Entomophthoramycosis. , 2010, , 3257-3269.		22
256	Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. Journal of Medical Microbiology, 2017, 66, 1124-1129.	0.7	53
257	Zygomycetes as Agents of Infectious Disease in Humans. , 0, , 429-440.		8
260	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3
261	Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis. , 0, , 2087-2108.		12
262	Susceptibility Test Methods: Yeasts and Filamentous Fungi. , 0, , 2255-2281.		11
263	In Vitro Activity of Amphotericin B in Combination with Statins against Clinical and Environmental Rhizopus oryzae Strains. Iranian Journal of Public Health, 0, , .	0.3	3

#	ARTICLE	IF	CITATIONS
264	Voriconazole in the management of nosocomial invasive fungal infections. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 129-157.	0.9	49
265	UNUSUAL PRESENTATION OF ENTOMOPHTHORIOMYCOSIS. <i>Indian Journal of Medical Microbiology</i> , 2009, 27, 156-158.	0.3	17
266	Mucormycosis in immunochallenged patients. <i>Journal of Emergencies, Trauma and Shock</i> , 2008, 1, 106.	0.3	52
267	æœ€è¿‘10ã1´é—“ã«ãñããã,«é‡Žèœã®³è™«ã®ç”ç©¶ã«ãã. <i>Proceedings of the Kansai Plant Protection Society</i> , 2008, 50, 39-44.	0.4	29
268	Rhino-orbital Mucormycosis: Clinical Findings and Treatment Outcomes of Four Cases. <i>Türk Oftalmoloji Dergisi</i> , 2015, 45, 169-174.	0.4	29
269	Establishment of Antimicrobial Stewardship Intervention to Promote the Appropriate Use of Antimicrobial Injection in All Inpatients and Outcomes Evaluation. <i>Iryo Yakugaku (Japanese Journal of)</i> Tj ETQq1 1 0784314 rgrBT /Over	0.4	29
270	The Mycoses. , 2006, , 530-542.		0
271	Dose Adjustment and Pharmacokinetics of Antibiotics in Severe Sepsis and Septic Shock. , 2007, , 122-146.		1
272	The Zygomycetes. , 2007, , 159-183.		2
273	ãf³ãfã,¾ãf³ãf%ãœãŽãããœãã,ãœãã,«éã»¶æœšèjœã°æjæ,ã°ç—‡ã,è³ã,ããã,œã¾ã. <i>Journal of the Japanese Society of Intensive Care Me</i>		2
274	Pharmacology of Azole Antifungal Agents. , 2009, , 199-218.		0
276	Zygomycosis. , 0, , 247-281.		0
277	Disseminated mucormycosis with cerebellum involvement due to <i>Rhizomucoriz/2pusillus</i> in a patient with multiple myeloma and secondary myelodysplastic syndrome: A case report. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4076-4080.	0.8	2
278	In Vitro Activity of Amphotericin B in Combination with Statins against Clinical and Environmental Strains. <i>Iranian Journal of Public Health</i> , 2019, 48, 943-948.	0.3	2
279	Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread. <i>Frontiers in Microbiology</i> , 2021, 12, 794176.	1.5	12
280	Utility of Itraconazole and Terbinafine in Mucormycosis: A Proof-of-Concept Analysis. <i>Journal of Investigative Medicine</i> , 2022, 70, 914-918.	0.7	11
281	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	1.3	1
282	Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022, 8, 44.	1.5	29



#	ARTICLE	IF	CITATIONS
283	COVID-19-associated mucormycosis: A review of an emergent epidemic fungal infection in the era of COVID-19 pandemic. Journal of Research in Medical Sciences, 2022, 27, 57.	0.4	7
284	AN OVERVIEW OF MUCORMYCOSIS. Innovare Journal of Health Science, 0, , 1-7.	0.0	0
285	Current treatments against mucormycosis and future directions. PLoS Pathogens, 2022, 18, e1010858.	2.1	21
287	Mucormycosis: A hidden mystery of fungal infection, possible diagnosis, treatment and development of new therapeutic agents. European Journal of Medicinal Chemistry, 2023, 246, 115010.	2.6	10
288	Mucormycosis: Prognosis and management. , 2023, , 309-321.		0
290	Disseminated <i>Mucor indicus</i> infection in a marmoset ( <i>Callithrix</i> sp.). Journal of Medical Primatology, 2023, 52, 190-193.	0.3	0
291	Rhino-Orbital Cerebral Mucormycosis: A Fatal Evolution. Cureus, 2023, , .	0.2	0
292	Emerging Mucormycosis: Problems and Treatments. , 2023, , 97-125.		0
294	Mucormycosis. , 2023, , 221-235.		0